264,43 +0,02 +0,01%
Official closure 02/10/2023 NYSE
More500. 79% of CFD retail accounts lose money
|News||Analyst Data||Analyst Opinions||internal activity||dividend table|
Will Stryker stock be bought, sold or held?Stryker stock received a consensus buy rating. The average rating is based on 43 buy reviews, 14 hold reviews and 1 sell rating.
What was Stryker's 52-week low?Stryker stock's 52-week low was 188.89. Based on current prices, Stryker is down 139.94% from its 52-week low.
What was the 52-week high for Stryker stock?Stryker stock's 52-week high was 283.88. Based on current prices, Stryker is 93.12% off its 52-week high.
What are analyst forecasts for Stryker stock?The 58 analysts providing price predictions for Stryker have an average target of 271.84, with a high estimate of 315.00 and a low estimate of 205.00. The middle guess is a difference of 97.24 from the last price of 264.34.
Stryker Instant Stock
ask the size
number of actions
At least 52 weeks
52 weeks high
free float in %
Book rated for sharing
cash flow per share
Zack's industry perspective highlights Stryker, Zimmer Biomet and Haemonetics
Stryker declares a dividend of $0.75
What Makes Stryker (SYK) a New Stock Buy?
Robert W. Baird maintains his buy rating on Stryker (SYK).
Stryker Historical Prices
|Data||Open||Fence||daily maximum||daily minimum|
Price change in the selected period:0%0
Stryker analyst data
Buy reviews:43 Neutral Ratings:14 Sales figures:1
Preis *Target price
Lower:205,00 Median:271,84 higher:315,00
*Average target price includes all analyst analysis, not just the most recent analysis shown on the chart.
Stryker Analyst Opinions
|02.02.23||Barclays Capital||keep buying||283 $||Colon|
|02.01.23||Morgan Stanley||restraint held back||280 $||neutral|
|02.01.23||Wells Fargo and company||keep buying||285 $||Colon|
|02.01.23||working capital||keep buying||290 $||Colon|
|02.01.23||BTIG survey||keep buying||281 $||Colon|
|02.01.23||capital telegram||restraint held back||250 $||neutral|
|02.01.23||RBC capital markets||keep buying||288 $||Colon|
|02.01.23||Baird Patrick and Company||keep buying||287 $||Colon|
|02.01.23||Citigroup Corp.||keep buying||290 $||Colon|
|02.01.23||Gaitero Sandler||keep buying||280 $||Colon|
|09.01.23||RBC capital markets||Updated to buy||284 $||Colon|
|01.06.23||Morgan Stanley||restraint held back||260 $||neutral|
|12.12.22||Wells Fargo and company||keep buying||281 $||Colon|
|02.12.22||Barclays Capital||keep buying||257 $||Colon|
|01.11.22||Wells Fargo and company||keep buying||248 $||Colon|
|01.11.22||RBC capital markets||restraint held back||240 $||neutral|
|01.11.22||capital telegram||Downgraded to keep||220 $||neutral|
|18.10.22||Barclays Capital||keep buying||239 $||Colon|
|17.10.22||BTIG survey||keep buying||232 $||Colon|
|10.12.22||Jefferies & Company Inc.||keep buying||270 $||Colon|
|14.09.22||Gaitero Sandler||keep buying||260 $||Colon|
|06.09.22||BTIG survey||keep buying||238 $||Colon|
|28.07.22||Edward Jones||Updated to buy||Colon|
|27.07.22||Wells Fargo and company||keep buying||237 $||Colon|
|27.07.22||RBC capital markets||restraint held back||255 $||neutral|
|27.07.22||Gaitero Sandler||keep buying||250 $||Colon|
|22.07.22||Cowen und Company, LLC||keep buying||223 $||Colon|
|21.07.22||Deutsche Bank||Downgraded to keep||$205||neutral|
|18.07.22||BTIG survey||keep buying||244 $||Colon|
|18.07.22||Stifel, Nicolaus & Co., Inc.||keep buying||245 $||Colon|
|15.07.22||Morgan Stanley||restraint held back||220 $||neutral|
|07.11.22||Bank of America Merrill Lynch||Downgraded to keep||$215||neutral|
|17.05.22||Citigroup Corp.||keep buying||280 $||Colon|
|02.05.22||Morgan Stanley||restraint held back||270 $||neutral|
|29.04.22||Gaitero Sandler||keep buying||290 $||Colon|
|29.04.22||Wells Fargo and company||keep buying||286 $||Colon|
|16.03.22||Bernstein||Updated to buy||295 $||Colon|
|15.03.22||Evercore||keep buying||284 $||Colon|
|31.01.22||Morgan Stanley||restraint held back||275 $||neutral|
|28.01.22||BTIG survey||keep buying||273 $||Colon|
|28.01.22||SVB Leerink||keep buying||285 $||Colon|
|01.07.22||Morgan Stanley||Downgraded to keep||305 $||neutral|
|04.01.22||Gaitero Sandler||Updated to buy||315 $||Colon|
|10.12.21||RBC capital markets||restraint held back||278 $||neutral|
|07.12.21||working capital||keep buying||305 $||Colon|
|19.11.21||Morgan Stanley||keep buying||305 $||Colon|
|28.07.21||capital telegram||keep buying||290 $||Colon|
|28.07.21||Morgan Stanley||keep buying||300 $||Colon|
|28.07.21||northern capital||Updated to buy||310 $||Colon|
|28.07.21||Swiss credit||keep buying||311 $||Colon|
Stryker estimates* in USD
|Dividend yield (in %)||1,09%||1,16%||1,48%||1,52%||-|
|Adjusted Net Income||3.832||4.253||4.659||5.147||5.528|
|profit before taxes||4.513||5.015||5.515||6.078||6.543|
|Net Income (Adjusted)||4.054||4.504||4.978||5.285||-|
|EPS (Non-GAAP) ej. S.O.E||8.91||9,98||10.97||-||-|
|investment cash flow||562||496||1.081||-603||-|
|Cash flow from operations||4.273||4.713||5.336||5.102||-|
|financing cash flow||-3.005||-2.990||-4.361||-1.564||-|
|cash flow per share||7,95||8.79||13.57||-||-|
|Free Cash Flow||3.285||3.672||4.293||-||-|
|Free cash flow per share||7.76||8.42||10.81||11.88||-|
|Book rated for sharing||48.24||54.14||59,39||-||-|
|Ext. of research and development||1.340||1.433||1.534||1.624||1.782|
|Sales, General and Administration. adult||6.450||6.891||7.341||7.809||8.178|
ends on 12/31/22
ends on 03/31/23
ends on 06/30/23
ends on 12/31/23
ends on 12/31/24
|Number of Analysts||26||24||24||27||24|
|average estimate||2.836 US-Dollar||2.000 $||2.366 US-Dollar||10.035 US-Dollar||11.125 US-Dollar|
|years before||2.710 US-Dollar||1.970 US-Dollar||$2.250||9.340 USD||10.035 US-Dollar|
|Number of Analysts||21||19||19||24||24|
|average estimate||4.964 US-Dollar||4.558 US-Dollar||4.813 $||19.785 $||21.164 US-Dollar|
|years before||4.701 $||4.275 $||4.493 US-Dollar||18.449 US-Dollar||19.785 $|
* Average estimates in millions (e.g. sales) or per share (e.g. dividends). Source: fact collection
Stryker internal activity
|Name||Data||shares traded||shares held||Preis||Type (sell/buy)||Possibility|
|STRYKER Ronda E||02.06.2023||20.832,00||4.730.754,00||273,37||Sell||NO|
|STRYKER Ronda E||02.06.2023||70.648,00||4.751.586,00||272,43||Sell||NO|
|STRYKER Ronda E||02.06.2023||23.196,00||4.822.234,00||271,27||Sell||NO|
|STRYKER Ronda E||02.06.2023||57.331,00||4.845.430,00||270,54||Sell||NO|
|STRYKER Ronda E||02.06.2023||17.930,00||4.902.761,00||269,31||Sell||NO|
|STRYKER Ronda E||02.06.2023||22.263,00||4.920.691,00||268,53||Sell||NO|
|STRYKER Ronda E||02.05.2023||8.780,00||4.942.954,00||280,97||Sell||NO|
|STRYKER Ronda E||02.05.2023||3.420,00||4.951.734,00||279,51||Sell||NO|
|STRYKER Ronda E||02.05.2023||8.000,00||4.955.154,00||278,18||Sell||NO|
|STRYKER Ronda E||02.05.2023||21.154,00||4.963.154,00||277.11||Sell||NO|
|STRYKER Ronda E||02.05.2023||29.808,00||4.984.308,00||276,05||Sell||NO|
|STRYKER Ronda E||02.05.2023||37.977,00||5.014.116,00||275,32||Sell||NO|
|STRYKER Ronda E||02.05.2023||23.008,00||5.052.093,00||274.13||Sell||NO|
|STRYKER Ronda E||02.05.2023||64.143,00||5.075.101,00||273,31||Sell||NO|
|STRYKER Ronda E||02.05.2023||34.333,00||5.139.244,00||272.21||Sell||NO|
|STRYKER Ronda E||02.05.2023||77.177,00||5.173.577,00||271,20||Sell||NO|
|Flechero Robert S||02.02.2023||3.000,00||6.636,00||283,54||Sell||NO|
|Pierce James Andrew||01.02.2023||400,00||46.676,00||277,88||Sell||NO|
|Pierce James Andrew||01.02.2023||7.128,00||47.076,00||278,95||Sell||NO|
|Becker Yin C||01.02.2023||2.412,00||21.684,00||278,95||Sell||NO|
|Böhnlein Glenn S||01.02.2023||125,00||2.428,00||279,96||Sell||NO|
|Böhnlein Glenn S||01.02.2023||8.883,00||2.553,00||279,52||Sell||NO|
|Böhnlein Glenn S||01.02.2023||7.708,00||11.436,00||278,38||Sell||NO|
|Böhnlein Glenn S||01.02.2023||7.709,00||19.144,00||277,55||Sell||NO|
|BerryWilliam E. Jr. . . . . .||01.02.2023||755,00||2.886,00||279,96||Sell||NO|
|Data||Name||Split||*to produce||To share|
|2022||Stryker Corporation.||2.83||1.16||US Dollar|
|2021||Stryker Corporation.||2.58||0,97||US Dollar|
|2020||Stryker Corporation.||2.35||0,96||US Dollar|
|2019||Stryker Corporation.||2.13||1.02||US Dollar|
|2018||Stryker Corporation.||1,93||1.23||US Dollar|
|2017||Stryker Corporation.||1,75||1.13||US Dollar|
|2016||Stryker Corporation.||1,56||1.31||US Dollar|
|2015||Stryker Corporation.||1.42||1.52||US Dollar|
|2014||Stryker Corporation.||1.26||1.34||US Dollar|
|2013||Stryker Corporation.||1.10||1.46||US Dollar|
|2012||Stryker Corporation.||0,90||1,65||US Dollar|
|2011||Stryker Corporation.||0,75||1.51||US Dollar|
|2010||Stryker Corporation.||0,63||1.17||US Dollar|
|2009||Stryker Corporation.||0,25||0,50||US Dollar|
|2008||Stryker Corporation.||0,40||1,00||US Dollar|
|2007||Stryker Corporation.||0,33||0,44||US Dollar|
|2006||Stryker Corporation.||0,22||0,40||US Dollar|
|2005||Stryker Corporation.||0,11||0,25||US Dollar|
|2004||Stryker Corporation.||0,09||0,19||US Dollar|
|2003||Stryker Corporation.||0,07||0,16||US Dollar|
|2002||Stryker Corporation.||0,06||0,18||US Dollar|
|2001||Stryker Corporation.||0,05||0,17||US Dollar|
|2000||Stryker Corporation.||0,04||0,16||US Dollar|
|1999||Stryker Corporation.||0,04||0,23||US Dollar|
* Fulfillment of the respective date
Stryker Corp calendar.
|result report||2.000 $||Earnings report for the first quarter of 2023||25.04.2023|
|result report||2.366 US-Dollar||Earnings report for the second quarter of 2023||25.07.2023|
|result report||-||Earnings report for the third quarter of 2023||26.10.2023|
|result report||-||Earnings report for the fourth quarter of 2023||24.01.2024|
Stryker Corp Past Events
|result report||3.000 $||Earnings report for the fourth quarter of 2022||31.01.2023|
Stryker Corp. is a medical technology company. It operates through the following segments: Orthopedics & Spine and Medical Surgery & Neurotechnology. The Orthopedics and Spine segment offers implants for use in total joint replacements such as hip, knee and shoulder, as well as for trauma and extremity surgeries. This segment also offers spinal implant products that include cervical and thoracolumbar systems used in spinal injuries, complex spinal and degenerative therapies. The MedSurg and Neurotechnology segment provides surgical equipment, safety technologies for patients and caregivers, and surgical navigation systems, endoscopic and communication systems, patient management, disposable medical equipment for emergency and critical care, remanufactured medical devices, and remanufactured and other medical device products used in various medical specialties . This segment also offers neurotechnology products, including products for minimally invasive endovascular techniques, products for cranial and brain-based surgical procedures, orthobiological and biosurgical products such as synthetic bone grafts and vertebral augmentation products, minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke, and products for cranial, maxillofacial implants, including cranial, maxillofacial, and chest wall devices; and dural sealants and substitutes. The company was founded by Homer H.
Moody's daily credit risk score
Moody's Daily Credit Risk Score is a 1 to 10 rating of a company's credit risk based on analysis of the company's balance sheet and stock market data. The score provides a one-year forecast of credit risk, enabling investors to make better decisions and streamline their workflows. It is updated daily and reflects daily movements in market value versus a company's liability structure.
|Vanguard Group, Inc.||7.57|
|Vanguard Group, Inc. (Subarquivador)||7.51|
|T. Rowe Price Associates, Inc. (Investitionsmanagement)||5.32|
|John Wilford Brown||5.30|
|Trust green leaf||5.19|
|Wellington Management Co. LLP||4,66|
|State Road Company.||3.71|
|Capital Research & Management Co. (global investors)||3.34|
|Fundo Vanguard Total Stock Market Index||2.74|
|BlackRock Fund Advisor||2.25|
|Vanguard 500 index funds||2.06|
|BlackRock Institutional Trust Co. NA||1,88|
|Vanguard Dividend Growth Fund||1,82|
|Geode Capital Management LLC||1.51|
Total equity ownership may be more than 100% as some owners are included in free float.
|Kevin A. Lobo||President, President and CEO|
|John Wilford Brown||emeritus president|
|Guillermo Eduardo Berry||Accounting Director and Vice President|
|Dana S. McMahon||Chief Compliance Officer and Vice President|
|Yin C. Becker||Director of Corporate Affairs and Vice President|
|Glenn S. Boehnlein||Chief Financial Officer and Vice President|
|M. Kathryn Fink||Head of Human Resources and Vice President|
|Alan Duville||Chief Information Officer and Vice President|
|Robert Fletcher||Legal Director and Vice President|
|Howard E. Cox||Director Emeritus|
|Preston Fountain||Chief Financial Officer and Vice President of Strykers Orthopedics Group|
|Viju S. Menon||Group President - Quality and Global Operations|
|Spencer S.Stiles||Group President - Orthopedics and Spine|
|Alan C. Golston||Independent Director|
|Ronda E Stryker||Independent Director|
|Lisa Skeete Tatum||Independent Director|
|Mary K. Brainerd||Independent Director|
|Juan Caforio||Independent Director|
|Srikant T. Madhav Datar||Independent Director|
|Andrew K. Silver Nails||Independent Director|
|Rajeev Suri||Independent Director|
|Sherilyn D McCoy||Chief Independent Director|
|Michael Panos||President of North America|
|Sean C. Etheridge||Secretary and Vice President|
|Juan Janik||Senior Director of Strategic Development|
|Juana M. Blondia||Treasurer and Vice President Finance|
|Jody Powell||Vice President of Global Regulatory Affairs and Quality Assurance|
|Irene B. Corbe||Vice President of Internal Audit|
|Jason Strand||Vice President of Investor Relations|
Is Stryker a good buy now? ›
Is Stryker Stock a good buy in 2023, according to Wall Street analysts? The consensus among 20 Wall Street analysts covering (NYSE: SYK) stock is to Buy SYK stock.Is Stryker a buy sell or hold? ›
Stryker has received a consensus rating of Buy. The company's average rating score is 2.65, and is based on 13 buy ratings, 7 hold ratings, and no sell ratings.What is Stryker price prediction? ›
Stryker Corp (NYSE:SYK)
The 22 analysts offering 12-month price forecasts for Stryker Corp have a median target of 262.50, with a high estimate of 284.00 and a low estimate of 205.00. The median estimate represents a +1.51% increase from the last price of 258.60.
Historical dividend payout and yield for Stryker (SYK) since 1993. The current TTM dividend payout for Stryker (SYK) as of February 07, 2023 is $3.00. The current dividend yield for Stryker as of February 07, 2023 is 1.11%.Is Stryker going to split? ›
The Stryker Corporation, a surgical and medical products maker, said today that it would split its stock 2 for 1. The split will double the number of shares to 194.4 million while halving the value of each share. The new shares will be issued May 12 to shareholders of record as of May 1.Will Stryker shares split? ›
Stryker - Stryker Corporation Announces Two-for-One Stock Split.Which is the best stock to hold? ›
- Reliance Industries. Multinational Conglomerate.
- Tata Consultancy Services (TCS) Information Technology.
- Infosys. Information Technology.
- HDFC Bank. Banking.
When is Stryker dividend payment date? Stryker's next quarterly payment date is on Jan 30, 2023, when Stryker shareholders who owned SYK shares before Dec 28, 2022 received a dividend payment of $0.75 per share. Add SYK to your watchlist to be reminded of SYK's next dividend payment.Is Surg stock a good buy? ›
If you are looking for stocks with good return, Surgepays Inc can be a profitable investment option. Surgepays Inc quote is equal to 5.570 USD at 2023-02-13. Based on our forecasts, a long-term increase is expected, the "SURG" stock price prognosis for 2028-02-02 is 13.608 USD.Is Stld a buy right now? ›
Valuation metrics show that Steel Dynamics, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of STLD, demonstrate its potential to outperform the market.
Should I buy Stkl stock? ›
Is Sunopta Stock a good buy in 2023, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: STKL) stock is to Buy STKL stock.Should I buy STLD stock? ›
Is Steel Dynamics Stock a good buy in 2023, according to Wall Street analysts? The consensus among 5 Wall Street analysts covering (NASDAQ: STLD) stock is to Hold STLD stock.What are the 5 highest dividend paying stocks? ›
- XRX. Xerox. Jan 26, 2023. ...
- IBM. International Business Machines. Jan 25, 2023. ...
- CVX. Chevron. Jan 27, 2023. ...
- EOG. EOG Resources. Nov 03, 2022. ...
- EPD. Enterprise Products Partners. Feb 01, 2023. ...
- ET. Energy Transfer. Nov 01, 2022. ...
- HESM. Hess Midstream Partners. Jan 25, 2023. ...
- ARCC. Ares Capital. Feb 07, 2023.
|High-yield dividend stock||Ticker||Dividend yield|
|Johnson & Johnson||(NYSE:JNJ)||2.57%|
|Medical Properties Trust||(NYSE:MPW)||9.76%|
Stryker completes acquisition of Vocera Communications.Which shares are going to split soon? ›
|Company||Old Face Value (Rs)||New Face Value (Rs)|
|RUCHIKA INDUSTRIES INDIA||5||1|
|Company||Stock Split Ratio||Payable Date|
|Amazon (NASDAQ:AMZN)||20-for-1||June 3, 2022|
|Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG)||20-for-1||July 15, 2022|
|Shopify (NYSE:SHOP)||10-for-1||June 28, 2022|
|DexCom (NASDAQ:DXCM)||4-for-1||June 10, 2022|
Should You Buy Before or After a Stock Split? Generally, the price of a stock moves higher following the announcement of a stock split. In a perfect world, investors could take advantage of this, but unfortunately, trading on knowledge of a stock split prior to its public disclosure is classified as insider trading.Is it better to buy before a stock split or after a stock split? ›
Any decision you make — buy, hold or sell — is not likely to have a much different outcome if you make it just before or just after the split. Since a stock split is announced prior to being executed, any post-split bump that the market expects is baked into the price by the time the split actually occurs.
Should you sell before or after a stock split? ›
Splits are often a bullish sign since valuations get so high that the stock may be out of reach for smaller investors trying to stay diversified. Investors who own a stock that splits may not make a lot of money immediately, but they shouldn't sell the stock since the split is likely a positive sign.What are the top 10 stocks to buy right now? ›
- Amazon.com, Inc. (NASDAQ: AMZN)
- The Walt Disney Company (NYSE: DIS)
- Palo Alto Networks, Inc. (NASDAQ: PANW)
- The Boeing Company (NYSE: BA)
- Prologis, Inc. (NYSE: PLD)
- Johnson & Johnson (NYSE: JNJ)
- MercadoLibre, Inc. (NASDAQ: MELI)
- Costco Wholesale Corporation (NASDAQ: COST)
- Berkshire Hathaway. Berkshire Hathaway (NYSE:BRK. ...
- The Walt Disney Company. ...
- Vanguard High-Dividend Yield ETF. ...
- Procter & Gamble. ...
- Vanguard Real Estate Index Fund. ...
- Starbucks. ...
Briefly, in order to be eligible for payment of stock dividends, you must buy the stock (or already own it) at least two days before the date of record and still own the shares at the close of trading one business day before the ex-date.Which company gives highest dividend every year? ›
- Indian Oil Corporation Limited.
- Indus Towers Limited.
- Hindustan Petroleum Corporation Limited.
- Coal India Limited.
- SJVN Limited.
- REC Limited.
- Power Finance Corporation Limited.
- Oil India Limited.
|SYK Split History Table|
|05/15/2000||2 for 1|
|05/17/2004||2 for 1|
- CVS. CVS Health Corp. premium. premium. ...
- LLY. Eli Lilly And Company. premium. premium. ...
- ABT. Abbott Laboratories. premium. premium. ...
- UNH. Unitedhealth Group Inc. premium. premium. ...
- PFE. Pfizer Inc. premium. premium. ...
- TDOC. Teladoc Inc. premium. ...
- NVS. Novartis AG. premium. ...
- JNJ. Johnson & Johnson. premium.
Surgepays Inc (NASDAQ:SURG)
The 2 analysts offering 12-month price forecasts for Surgepays Inc have a median target of 12.00, with a high estimate of 15.00 and a low estimate of 9.00.
That said, market sentiment can turn on a dime, and history suggests this will happen long before the downturn is over. Furthermore, many stocks are cheaper than they've been in some time. That's why right now is the best time to invest in the stock market.What is the outlook for Steel Dynamics? ›
Over the last 12 months, its price rose by 104.49 percent. Looking ahead, we forecast Steel Dynamics to be priced at 115.03 by the end of this quarter and at 104.08 in one year, according to Trading Economics global macro models projections and analysts expectations.
Is Steel Dynamics a buy or sell? ›
Steel Dynamics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Is Steel Dynamics a buy sell or hold? ›
The Steel Dynamics stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.Should I sell VXRT stock? ›
Vaxart has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Is SGH a good buy? ›
Out of 5 analysts, 4 (80%) are recommending SGH as a Strong Buy, 1 (20%) are recommending SGH as a Buy, 0 (0%) are recommending SGH as a Hold, 0 (0%) are recommending SGH as a Sell, and 0 (0%) are recommending SGH as a Strong Sell.Is CRSR a buy or sell? ›
Corsair Gaming's analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts. How can I buy shares of CRSR?Is Power metals a good investment? ›
Our Ai stock analyst implies that there will be a negative trend in the future and the PWM shares are not a good investment for making money.What is Steel Dynamics debt to equity ratio? ›
The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Steel Dynamics debt/equity for the three months ending December 31, 2022 was 0.38.Should I sell my Oracle stock? ›
Oracle has received a consensus rating of Buy. The company's average rating score is 2.52, and is based on 13 buy ratings, 9 hold ratings, and 1 sell rating.Do you pay taxes on dividends? ›
Yes – the IRS considers dividends to be income, so you usually need to pay taxes on them. Even if you reinvest all of your dividends directly back into the same company or fund that paid you the dividends, you will pay taxes as they technically still passed through your hands.How much taxes do you pay on dividends? ›
The tax rates for ordinary dividends are the same as standard federal income tax rates; 10% to 37%.
What are the top 10 dividend stocks to buy? ›
- Dow Inc. ...
- International Business Machines (IBM) ...
- Verizon Communications (VZ) ...
- AT&T (T) ...
- Intel (INTC) ...
- Philip Morris International (PM) ...
- Walgreens Boots Alliance (WBA) ...
- 3M Company (MMM)
Stryker scored higher in 9 areas: Overall Rating, Culture & Values, Work-life balance, Senior Management, Compensation & Benefits, Career Opportunities, CEO Approval, Recommend to a friend and Positive Business Outlook. Stryker employees rated their Recommend to a friend 5% higher than Medtronic employees rated theirs.What is the most stable stock to invest in? ›
Best safe stocks to buy
- Berkshire Hathaway. ...
- The Walt Disney Company. ...
- Vanguard High-Dividend Yield ETF. ...
- Procter & Gamble. ...
- Vanguard Real Estate Index Fund. ...
- Starbucks. ...
Momentum Scorecard. More Info.
|Zacks Rank||Definition||Annualized Return|
|Best Value Healthcare Stocks|
|Price ($)||12-Month Trailing P/E Ratio|
|Azenta Inc. (AZTA)||56.56||2.0|
|QuidelOrtho Corp. (QDEL)||86.28||4.6|
|Moderna Inc. (MRNA)||190.38||6.9|
Stryker competitors include Johnson & Johnson, Medtronic, GE Healthcare, Globus Medical and DJO Global. Stryker ranks 1st in CEO Score on Comparably vs its competitors.Who owns the most Stryker stock? ›
Stryker Success Story. Leading with integrity, committing to customers, understanding the strengths of employees and staying ahead of the competition: Stryker proves that large organizations, specifically within the competitive field of healthcare, can choose integrity and dedication to outperform the competition.